Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer

Zhang,Ying; Ying,Xia; Han,Suxia; Wang,Jing; Zhou,Xia; Bai,E; Zhang,Jianying; Zhu,Qing

doi:10.3892/ijo.2012.1699

Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer

Authors:
- Ying Zhang
- Xia Ying
- Suxia Han
- Jing Wang
- Xia Zhou
- E Bai
- Jianying Zhang
- Qing Zhu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University Medical Center, Xi'an, Shaanxi 710061, P.R. China
Published online on: November 15, 2012 https://doi.org/10.3892/ijo.2012.1699
Pages: 93-100
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin-like growth factor-binding protein-2 (IGFBP-2) is considered to be a human tumor antigen, and the tumor-speciﬁc immunity of IGFBP-2 has been reported in several types of cancer. The purpose of this study was to evaluate whether autoantibodies to IGFBP-2 can be used as diagnostic markers in lung cancer. The results demonstrated that serum anti-IGFBP-2 autoantibody levels were signiﬁcantly elevated in lung cancer (mean, 1,633.318 ng/ml; median, 1,651.462 ng/ml; range, 342.732-4932.582 ng/ml) compared with benign lung disease (1,210.139, 1,035.900, 547.596‑2,331.167 ng/ml) and normal controls (1,303.369, 1,194.800, 528.200-2140.500 ng/ml). The sensitivity and speciﬁcity of anti-IGFBP-2 autoantibodies in diagnosing lung cancer was 73.2 and 60.6%, respectively. When serum IGFBP-2 and anti-IGFBP-2 autoantibody were used together in the diagnosis of lung cancer, it can increase the discriminative power for lung cancer with a sensitivity of 85.7% and a specificity of 57.5%. In conclusion, this study demonstrates that circulating anti-IGFBP-2 autoantibodies can be used as a potential biomarker in diagnosing lung cancer.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
2.	Woodward RM, Brown ML, Stewart ST, Cronin KA and Cutler DM: The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer. 110:2511–2518. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Ernst A, Anantham D, Eberhardt R, Krasnik M and Herth FJ: Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol. 3:577–582. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Nakashima A, Murakami Y, Uemura K, et al: Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas. 38:527–533. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Ghaneh P, Greenhalf W, Humphreys M, et al: Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 8:199–208. 2007. View Article : Google Scholar
6.	Soussi T: p53 antibodies in the sera of patients with various types of cancer. Cancer Res. 60:1777–1788. 2010.PubMed/NCBI
7.	Looi K, Megliorino R, Shi FD, Peng XX, Chen Y and Zhang JY: Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 16:1105–1110. 2006.PubMed/NCBI
8.	Zhang JY, Chan EK, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 189:1101–1110. 1999. View Article : Google Scholar : PubMed/NCBI
9.	Park KH, Gad E, Goodell V, et al: Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 68:8400–8409. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Lin Y, Jiang T, Zhou K, et al: Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. 11:468–476. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Miraki-Moud F, Jenkins PJ, Fairclough PD, et al: Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxf). 54:499–508. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Liou JM, Shun CT, Liang JT, et al: Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Shariat SF, Lamb DJ, Kattan MW, et al: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Wang H, Rosen DG, Wang H, Fuller GN, Zhang W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 58:361–366. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Baron-Hay S, Boyle F, Ferrier A and Scott C: Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 10:1796–1806. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Li Y, Jiang T, Zhang J, et al: Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies. Ann Oncol. 23:2415–2422. 2012. View Article : Google Scholar
18.	Pereira JJ, Meyer T, Docherty SE, Reid HH, et al: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 64:977–984. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Wang GK, Hu L, Fuller GN and Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 281:14085–14091. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Hoeflich A, Reisinger R, Lahm H, et al: Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter. Cancer Res. 61:8601–8610. 2001.PubMed/NCBI
21.	Lee EJ, Mircean C, Shmulevich I, et al: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer. 4:72005. View Article : Google Scholar : PubMed/NCBI
22.	Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M and Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 13:341–345. 2005.
23.	Schütt BS, Langkamp M, Rauschnabel U, Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 32:859–868. 2004.PubMed/NCBI
24.	Hoeflich A, Reisinger R, Schuett BS, et al: Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun. 324:705–710. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Hoeflich A, Fettscher O, Lahm H, et al: Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 60:834–838. 2000.PubMed/NCBI
26.	Chatterjee S, Park ES and Soloff MS: Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol. 11:876–884. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Vorwerk P, Mohnike K, Wex H, Röhl FW, Zimmermann M, Blum WF and Mittler U: Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab. 90:3022–3027. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Mehrian-Shai R, Chen CD, Shi T, et al: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W and El-Deiry WS: Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther. 5:1408–1414. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Migita T, Narita T, Asaka R, et al: Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 176:1756–1766. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A and Wild CP: p53 antibodies in patients with various types of cancer assay, identification, and characterization. Clin Cancer Res. 1:1463–1469. 1995.PubMed/NCBI
32.	Comtesse N, Zippel A, Walle S, et al: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci USA. 102:9601–9606. 2005. View Article : Google Scholar